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Dear Editor,
In a recent issue of your journal, we were grateful to read
the enjoyable article by Caram et al. (1), which evaluated the
prevalence of electrocardiographic and echocardiographic
abnormalities in patients with chronic obstructive pulmon-
ary disease (COPD) according to disease severity (25 mild/
moderate and 25 severe/very severe COPD patients). The
study showed that COPD patients have a high prevalence of
left ventricular diastolic dysfunction (LVDD) and that this
dysfunction is associated with disease severity. The authors
also concluded that because of this close association, it is
important to exclude decompensated heart failure (HF)
during the evaluation of COPD exacerbation.
Heart failure and COPD are the most common causes of
mortality worldwide (2). The two diseases have significant
overlap with regard to risk factors and pathophysiological
mechanisms (including systemic inflammation), resulting
in diagnostic and therapeutic challenges for both emer-
gency department and outpatient physicians (3,4).
Approximately 10–40% of patients with HF have reported
concomitant COPD (3). Additionally, the prevalence of
unrecognized HF was 20.9% in patients with COPD or
asthma presenting to the emergency department (5), and
this prevalence was reported as 20.5 and 17% in commu-
nity patients with stable COPD (6,7). In addition to the
similarity in mechanism, both conditions may present with
highly similar symptoms, including dyspnea, orthopnea,
coughing, exercise intolerance, fatigue, muscle weakness,
disturbed sleep, anorexia, and anxiety (8). Caram et al. (1)
noted that patients with COPD have significant echocar-
diographic abnormalities, independent of disease severity
(98%). The most frequently noted echocardiographic
abnormality was mild LVDD (88%). Of the several studied
risk factors, COPD severity was the only significant
predictor of LVDD, which might explain the common
pathophysiological pathways in both conditions. However,
this association should be coupled with follow-up data
demonstrating that the concurrent presence of HF and
COPD can increase morbidity and mortality. The findings
of Caram et al. (1) demonstrated that HF and COPD are
common and frequently concomitant conditions in patients
with COPD that can be screened for using transthoracic
echocardiography, an acceptable, safe, valid, and reliable
imaging modality applicable to the COPD population. In
addition to imaging techniques, concurrent HF and COPD
exacerbations can be differentiated by biochemical tests,
including natriuretic peptides (such as brain natriuretic
peptide). Natriuretic peptides provide additional diagnostic
accuracy and might be the most effective tool in refining the
diagnosis for this patient population, given the high negative
predictive value of a normal result. However, through the
effects on pulmonary artery pressure and right-ventricular
overload, COPD can also cause elevated circulating levels of
natriuretic peptides (9,10). Despite this potential confounding
factor, the negative predictive accuracy of natriuretic
peptides for ruling out acute decompensated HF appears to
be preserved, even in cohorts of patients with both HF and
COPD diagnoses (5,11).
In conclusion, this study demonstrated that patients with
COPD have significant electrocardiographic and echocar-
diographic abnormalities, independent of disease severity.
Among all of the pathological findings, LVDD is of great
importance because of the prognostic role it plays in
patients with COPD. As diagnosing cardio-pulmonary
interaction is a complex process, LVDD in COPD patients
can be best addressed through simple clinical measures,
including natriuretic peptides and objective measurements
of ventricular dysfunction by echocardiography.
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